WO2016201374A1 - Dérivés d'adénosine sulfanide et leurs utilisations - Google Patents

Dérivés d'adénosine sulfanide et leurs utilisations Download PDF

Info

Publication number
WO2016201374A1
WO2016201374A1 PCT/US2016/037092 US2016037092W WO2016201374A1 WO 2016201374 A1 WO2016201374 A1 WO 2016201374A1 US 2016037092 W US2016037092 W US 2016037092W WO 2016201374 A1 WO2016201374 A1 WO 2016201374A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
optionally substituted
certain embodiments
formula
pharmaceutically acceptable
Prior art date
Application number
PCT/US2016/037092
Other languages
English (en)
Inventor
Xin Qi
Ravil KHAYBULLIN
Xiao Liang
Original Assignee
University Of Florida Research Foundation, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Florida Research Foundation, Incorporated filed Critical University Of Florida Research Foundation, Incorporated
Publication of WO2016201374A1 publication Critical patent/WO2016201374A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

L'invention concerne des dérivés d'adénosine sulfamide de formule (I) ou (II), ainsi que leurs sels pharmaceutiquement acceptables et les compositions pharmaceutiques les comprenant. L'invention concerne également des procédés, des utilisations et des kits impliquant ces composés ou compositions pharmaceutiques pour le traitement et/ou la prévention de maladies prolifératives (par ex., des cancers, des maladies inflammatoires et des maladies auto-immunes) ou de maladies infectieuses (par ex., des infections bactériennes, les infections virales, des infections fongiques et des maladies parasitaires) chez un sujet. Les composés et les compositions pharmaceutiques selon l'invention sont censées inhiber l'activité aminoacyl-ARNt synthétase dans un échantillon biologique ou chez un sujet pour obtenir le traitement de maladies prolifératives ou de maladies infectieuses.
PCT/US2016/037092 2015-06-11 2016-06-10 Dérivés d'adénosine sulfanide et leurs utilisations WO2016201374A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562174362P 2015-06-11 2015-06-11
US62/174,362 2015-06-11

Publications (1)

Publication Number Publication Date
WO2016201374A1 true WO2016201374A1 (fr) 2016-12-15

Family

ID=57504547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/037092 WO2016201374A1 (fr) 2015-06-11 2016-06-10 Dérivés d'adénosine sulfanide et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2016201374A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3645561A4 (fr) * 2017-06-30 2021-11-17 Memorial Sloan-Kettering Cancer Center Compositions et méthodes de thérapie cellulaire adoptive contre le cancer
WO2023288275A3 (fr) * 2021-07-14 2023-03-23 The Regents Of The University Of California Systèmes et procédés d'évaluation de modifications de nucléobase

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498601A (en) * 1992-07-09 1996-03-12 Nippon Steel Corporation Platelet aggregation-inhibiting peptides
US5824657A (en) * 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US20080293666A1 (en) * 2005-12-06 2008-11-27 Regents Of The University Of Minnesota Antibacterial Agents
US20090170805A1 (en) * 2005-04-15 2009-07-02 Derek Shieh Tan Anti-microbial agents and uses thereof
US8927533B2 (en) * 2011-09-19 2015-01-06 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498601A (en) * 1992-07-09 1996-03-12 Nippon Steel Corporation Platelet aggregation-inhibiting peptides
US5824657A (en) * 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US20090170805A1 (en) * 2005-04-15 2009-07-02 Derek Shieh Tan Anti-microbial agents and uses thereof
US20080293666A1 (en) * 2005-12-06 2008-11-27 Regents Of The University Of Minnesota Antibacterial Agents
US8927533B2 (en) * 2011-09-19 2015-01-06 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERNIER ET AL.: "Glutamylsulfamoyladenosine and pyroglutamylsulfarnoyladenosine are competitive inhibitors of E. coli glutamyl-tRNA synthetase", J ENZYME INHIB MED CHEM., vol. 20, no. 1, 2005, pages 617 *
DATABASE PUBCHEM [O] 11 August 2008 (2008-08-11), XP055333926, Database accession no. 24866955 *
DATABASE PUBCHEM [O] 19 January 2008 (2008-01-19), XP055333925, Database accession no. 23647961 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3645561A4 (fr) * 2017-06-30 2021-11-17 Memorial Sloan-Kettering Cancer Center Compositions et méthodes de thérapie cellulaire adoptive contre le cancer
WO2023288275A3 (fr) * 2021-07-14 2023-03-23 The Regents Of The University Of California Systèmes et procédés d'évaluation de modifications de nucléobase

Similar Documents

Publication Publication Date Title
AU2017363313B2 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
US10723753B2 (en) Ras inhibitors and uses thereof
AU2017363307B2 (en) Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
WO2018085247A1 (fr) Composés pour la dégradation de malt1
EP3341007B1 (fr) Inhibiteurs de malt1 et leurs utilisations
WO2018165385A1 (fr) Inhibiteurs de malt1 et leurs utilisations
AU2021203883A1 (en) Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
EP3876939A1 (fr) Dérivés benzothiazoles et dérivés 7-aza benzothiazoles comme inhibiteurs de la janus kinase 2 et leurs utilisations
US20220395509A1 (en) A pyrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases
WO2016201374A1 (fr) Dérivés d'adénosine sulfanide et leurs utilisations
EP3383852A2 (fr) Composés pour traiter des maladies prolifératives
WO2016077581A1 (fr) Triazoles d'isostéviol et leurs utilisations
AU2016348452A1 (en) Polyamine sulfonamides and uses thereof
WO2023196714A2 (fr) Inhibiteurs de ddr1 et ddr2 pour le traitement de l'arthrite
EP3471723A1 (fr) Inhibiteurs d'acyltransférase hedgehog et utilisations de ces derniers
WO2024077023A2 (fr) Agents de dégradation doubles de bcl-xl/bcl-2 de recrutement de céréblon

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16808479

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16808479

Country of ref document: EP

Kind code of ref document: A1